Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated ...

Relyvrio takes the form of a powder that is mixed with water and can be taken via a feeding tube, and has been approved based on the phase 2 CENTAUR trial in patients with fast-progressing ALS ...

(The Hill) — The maker of a drug to treat ALS says it will withdraw the medication from the market after it recently failed a large clinical trial. Amylyx Pharmaceuticals said it will halt sales ...